Improving predictions about brain cancer outcomes with the right imaging criteria
A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...
The American Journal of Managed Care1d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) ...
Monthly Prescribing Reference1d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.
Targeted Oncology1d
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...
FiercePharma1d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Targeted Oncology7d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Oncology Nurse Advisor7h
Dabrafenib-Trametinib Combo Shows Activity as Second-Line Adjuvant Therapy in Advanced Melanoma
Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...
Pharmaceutical Technology4d
Nivolumab by Bristol-Myers Squibb for Peritoneal Cancer: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Peritoneal Cancer.
Renal & Urology News1mon
Adding Nivolumab to Tivozanib Provides No Benefit in RCC After Prior ICI
Results from the phase 3 TiNivo-2 trial suggest that immune checkpoint inhibitor rechallenge should generally be discouraged ...
Pharmaceutical Technology4d
(Nivolumab + relatlimab) by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.
Cancer Therapy Advisor3d
Opdivo Qvantig Approved to Treat Solid Tumor Malignancies
The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.